共 50 条
- [41] Endometrial Carcinoma with Mucinous Differentiation and Kras G12D Mutation Is Associated with Lymph Node Metastasis and Vaginal RecurrenceMODERN PATHOLOGY, 2013, 26 : 298A - 299AXiong, J.He, M.Jackson, C.Breese, V.Sung, C. J.Steinhoff, M. M.Quddus, M. R.Tejadaberges, T.Lawrence, W. D.
- [42] Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcomeJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Ardalan, BachCiner, AaronBaca, YasmineDarabi, SouratKasi, AnupLou, EmilAzqueta, Jose IgnacioXiu, JoanneNabhan, ChadiShields, Anthony F.Aguirre, AndrewSingh, HarshabadShroff, Rachna T.Pishvaian, Michael J.Goel, Sanjay
- [43] MEK inhibitor-based therapy in metastatic pancreatic adenocarcinoma with KRAS G12D or KRAS G12V alteration.JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 726 - 726Ying, GraceAuckley, ElizabethAldakkak, MohammedThalji, Samih Z.Vakili, ParnianGrahl, JustinMayer, BradleyShahjehan, FaisalLow, Soon KhaiEvans, Douglas B.Christians, Kathleen K.Seo, Yongwoo DavidErickson, BethHall, William AdrianMcfall, ThomasKurzrock, RazelleGeorge, BenKamgar, Mandana
- [44] Endometrial Carcinoma with Mucinous Differentiation and Kras G12D Mutation Is Associated with Lymph Node Metastasis and Vaginal RecurrenceLABORATORY INVESTIGATION, 2013, 93 : 298A - 299AXiong, J.He, M.Jackson, C.Breese, V.Sung, C. J.Steinhoff, M. M.Quddus, M. R.Tejadaberges, T.Lawrence, W. D.
- [45] Mutation-Specific and Common Phosphotyrosine Signatures of KRAS G12D and G13D AllelesJOURNAL OF PROTEOME RESEARCH, 2021, 20 (01) : 670 - 683Tahir, RaihaRenuse, SantoshUdainiya, SavitaMadugundu, Anil K.Cutler, Jevon A.Nirujogi, Raja SekharNa, Chan HyunXu, YaoyuWu, XinyanPandey, Akhilesh
- [46] Structure-Based Design and Synthesis of Potent and Selective KRAS G12D InhibitorsACS MEDICINAL CHEMISTRY LETTERS, 2023, 14 (10): : 1351 - 1357Cheng, HengmiaoLi, PuhuiChen, PingIrimia, AdrianaBae, Jae HyunBrooun, AlexeiFagan, PatrickLam, RichardLin, BingzhenZhang, JingchuanZhan, XuejunWu, XuXie, NanChiang, GaryShoemaker, RobertVernier, Jean-Michel
- [47] KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogrammingNATURE, 2023, 619 (7971) : 860 - +Juul, Nicholas H.Yoon, Jung-KiMartinez, Marina C.Rishi, NehaKazadaeva, Yana I.Morri, MaurizioNeff, Norma F.Trope, Winston L.Shrager, Joseph B.Sinha, RahulDesai, Tushar J.
- [48] Targeting KRAS G12D mutant tumors with the PROTAC degrader RP03707CANCER RESEARCH, 2024, 84 (06)Ji, XiangLi, HuanpingWu, GangZhang, QiguoHe, XiaolinWu, YanpengZong, BingXu, XiaojinLiang, ChaoWang, BeibeiZhang, YuweiHu, QingyaoZhou, JiaxinGuo, WeihuiBai, BingWang, LinAi, JinchaoZhang, LeduoZhou, HongguiSun, ShihaoWang, YijieWang, YouhongFan, QimingChen, DaweiZhou, TianlunLu, Jiasheng
- [49] KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogrammingNature, 2023, 619 : 860 - 867Nicholas H. JuulJung-Ki YoonMarina C. MartinezNeha RishiYana I. KazadaevaMaurizio MorriNorma F. NeffWinston L. TropeJoseph B. ShragerRahul SinhaTushar J. Desai
- [50] KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridgeCELL DISCOVERY, 2022, 8 (01)Mao, ZhongweiXiao, HongyingShen, PanpanYang, YuXue, JingYang, YunyunShang, YanguoZhang, LilanLi, XinZhang, YuyingDu, YananChen, Chun-ChiGuo, Rey-TingZhang, Yonghui